Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 5, 2011, Pages 627-634

  Accurso, Frank J ^a   Moss, Richard B ^b   Wilmott, Robert W ^c   Anbar, Ran D ^d   Schaberg, Amy E ^e   Durham, Todd A ^e   Ramsey, Bonnie W ^f   Ahrens, R ^g   Anbar, R ^h   Lindner, D ^h   Anderson, P ⁱ   Atlas, A ^j   Berthiaume, Y ^k   Beaudoin, N ^k   Bisberg, D ^l   Pock, P ^l   Boas, S ^m   Borowitz, D ⁿ   Smith, J ⁿ   Chidekel, A S ^o   Chipps, B ^p   Chmiel, J F ^q   Ksenich, B ^q   Clancy, J P ^r   Colombo, J ^s   Heimes, D ^s   Daines, C ^t   DeCelie Germana, J ^u   Galvin, S ^u   Deterding, R ^v   DiMango, E ^w   Dorkin, H ^x   Dozor, A ^y   Gherson, I ^y   Dunitz, J ^z   Egan, M ^aa   Young, J ^aa   Elliott, G ^ab   Gadd, J ^ab   Fornos, P ^ac   Franco, M ^ad   Froh, D ^ae   Kelly, R ^ae   Geller, D ^af   Cook, D ^af   Gibson, R ^f   Genatossio, A ^f   Gong, G ^ag   Graff, G ^ah   Hardy, K ^ai   Robles, A ^ai   Hicks, D ^aj   Howenstine, M ^ak   Bendy, L ^ak   Jones, K ^al   Gardner, A ^al   Kanga, J ^am   Owsley, B ^am   Kreindler, J ^an   Lapin, C ^ao   Drapeau, G ^ao   Lee, R ^ap   Dillard, M ^ap   Liou, T ^aq   McCoy, K S ^ar   Olson, P ^ar   Millard, S ^as   Moss, R ^b   Dunn, C ^b   Davies, Z ^b   Nakamura, C ^at   Brascia, T ^at   Nasr, S ^au   Oermann, C ^av   Traplena, L ^av   Prestidge, C ^aw   Prestridge, A ^ax   Delute, D ^ax   Ren, C ^ay   Retsch Bogart, G ^az   Towle, D ^az   Barlow, C ^az   Reyes, S ^ba   Roberts, D ^bb   Roberts, V ^bb   Rock, M ^bc   Makholm, L ^bc   Rubenstein, R ^bd   Kubrak, C ^bd   Murray, C ^bd   Schaeffer, D ^be   DeLuca, E ^be   Schechter, M ^bf   Peabody, J ^bf   Schellhase, D ^bg   Walker, P ^bh   Grece, C ^bh   Wall, M ^bi   Guzik, A ^bi   Weiner, D ^an   Horn, A ^an   Willey Courand, D B ^bj   Kociela, V ^c   Woo, M ^bk   Wooldridge, J ^t   Duan, L ^t   Zeitlin, P ^bl   Zuckerman, J ^bm   Kennedy DuDevoir, R ^bm   more..

^a UNIVERSITY OF COLORADO   (United States)

^b STANFORD UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h University Hospital   (United States)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^j MORRISTOWN MEMORIAL HOSPITAL   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l SAINT BARNABAS MEDICAL CENTER   (United States)

^m Cystic Fibrosis Center of Chicago   (United States)

ⁿ UNIVERSITY AT BUFFALO   (United States)

^o NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^p Capital Allergy and Respiratory Disease Center   (United States)

^q UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^t CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^u SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^v CHILDREN S HOSPITAL COLORADO   (United States)

^w NewYork Presbyterian Hospital   (United States)

^x BOSTON CHILDREN S HOSPITAL   (United States)

^y NEW YORK MEDICAL COLLEGE   (United States)

^z UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^aa YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ab Pediatric Pulmonary Clinic   (United States)

^ac Alamo Heart Associates   (United States)

^ad MIAMI CHILDREN'S HOSPITAL   (United States)

^ae UNIVERSITY OF VIRGINIA   (United States)

^af NEMOURS CHILDREN S HOSPITAL   (United States)

^ag PHOENIX CHILDREN'S HOSPITAL   (United States)

^ah PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^ai Bay Area Pediatrics   (United States)

^aj CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^ak RILEY HOSPITAL FOR CHILDREN   (United States)

^al LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^am UNIVERSITY OF KENTUCKY   (United States)

^an CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^ao Farmington   (United States)

^ap NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^aq UNIVERSITY OF UTAH   (United States)

^ar NATIONWIDE CHILDREN S HOSPITAL   (United States)

^as SPECTRUM HEALTH   (United States)

^at Children's Lung Specialists Ltd   (United States)

^au UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^av BAYLOR COLLEGE OF MEDICINE   (United States)

^aw CHILDREN S MEDICAL CENTER   (United States)

^ax CHILDREN'S MEMORIAL HOSPITAL   (United States)

^ay UNIVERSITY OF ROCHESTER   (United States)

^az UNIVERSITY OF NORTH CAROLINA   (United States)

^ba UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^bb Pediatric Breathing Disorders   (United States)

^bc University of Wisconsin Health   (United States)

^bd CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^be NEMOURS CHILDREN S CLINIC   (United States)

^bf EMORY UNIVERSITY   (United States)

^bg ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

^bh ST VINCENT S HOSPITAL   (United States)

^bi OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^bj UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^bk CHILDREN S HOSPITAL LOS ANGELES   (United States)

^bl JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bm MAINE MEDICAL CENTER   (United States)

more..

Author keywords

Chloride channel activator; Early intervention; ENaC inhibition; Ion channel regulator; P2y2 receptor agonist

Indexed keywords

DENUFOSOL; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SINUSITIS; SORE THROAT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYCYTOSINE NUCLEOTIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG; MALE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URIDINE; YOUNG ADULT;

EID: 79952211206     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201008-1267OC     Document Type: Article

References (44)

1. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008;77:701-726.
2. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007;261:5-16. (Pubitemid 46046468)
3. Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, Hoo AF, Lum S, Price J, Ranganathan S, et al.; London Cystic Fibrosis Collaboration. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-49. (Pubitemid 351919192)
4. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, Robertson CF, Robinson PJ, Franklin PJ, Turner SW, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008;178:1238-1244.
5. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-161. (Pubitemid 38869388)
6. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180:146-152.
7. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, Gangell CL, De Klerk N, Linnane B, Ranganathan S, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009;155:623-628.e1.
8. Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010;9:1-16.
9. Tiddens HAWM, Donaldson SH, Rosenfeld M, Pare PD. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 2010;45:107-117.
10. Ranganathan S, Linnane B, Nolan G, Gangell C, Hall G. Early detection of lung disease in children with cystic fibrosis using lung function. Paediatr Respir Rev 2008;9:160-167.
11. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJ. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008;322:590-594.
12. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008;455:1210-1215.
13. Schroeder BC, Cheng T, Jan YN, Jan LY. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008;134:1019-1029.
14. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R, Boyer J, et al. Pharmacology of INS37217 [P1-(uridine 5′)-P4- (2′-deoxycytidine 5′)tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002;302:871-880. (Pubitemid 34920206)
15. Rock JR, O'Neal WK, Gabriel SE, Randell SH, Harfe BD, Boucher RC, Grubb BR. Transmembrane protein 16A (TMEM16A) is a Ca2+-regulated Cl- secretory channel in mouse airways. J Biol Chem 2009;284:14875-14880.
16. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: a review of studies with inhaled P2Y2 agonists that led to phase 3. Pulm Pharmacol Ther 2008;21:600-607. (Pubitemid 351970709)
17. Kunzelmann K, Bachhuber T, Regeer R, Markovich D, Sun J, Schreiber R. Purinergic inhibition of the epithelial Na+ transport via hydrolysis of PIP2. FASEB J 2005;19:142-143. (Pubitemid 40069945)
18. Lazarowski ER, Boucher RC. Purinergic receptors in airway epithelia. Curr Opin Pharmacol 2009;9:262-267.
19. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, et al.; Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339-348.
20. Deterding RR, LaVange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW; Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103Working Group. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;176:362-369. (Pubitemid 47267470)
21. Moss RB, Anbar RD, Wilmott RW, Barnes M, Schaberg AE, Durham TA, Accurso FJ. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis [abstract]. Am J Respir Crit Care Med 2009;179:A1189.
22. Mospan AR, Durham TA, Schaberg AE, Accurso FJ. Effects of denufosol on sinusitis-related complaints in a phase 3 trial in cystic fibrosis patients [abstract]. J Cyst Fibros 2009;8:S26.
23. Accurso FJ, Durham TA, Schaberg AE. Relationship between pulmonary exacerbations and lung function decline in a six month trial of denufosol [abstract]. J Cyst Fibros 2009;8:S26.
24. Navratil T, Schaberg A, Mathews D, Deans C, Durham T, Accurso FJ. Pharmacological treatment of CF: lessons learned from a phase 3 clinical trial [abstract]. Pediatr Pulmonol Suppl 2009;32:416.
25. Durham T, Navratil T, Schaberg A, Deans C, Smiley L, Herje N, Retsch-Bogart G, Accurso FJ. Concomitant medication use in patients with mild cystic fibrosis lung disease assigned to placebo in Phase 3 clinical trial of denufosol (Study 08-108/TIGER-1) [abstract]. Am J Respir Crit Care Med 2010;181:A1842.
26. Navratil T, Schaberg A, Tian W, Durham T, Evans C, Lindroos C, Barrus S, Mathews D, Barnes M, Ratjen F, et al. Potential of denufosol as an early intervention therapy for CF lung disease [abstract]. FASEB J 2010;24:31.
27. Moss RB, Schaberg A, Deans C, Tian W, Smiley L, Herje N. Denufosol improves lung function in adolescent CF patients [abstract]. J Cyst Fibros 2010;9:S20.
28. Navratil T, Evans C, Schaberg A, Johnson F, Durham T, Ren CL, Ratjen F, Moss RB, Accurso FJ. Aerosol and pharmacokinetic properties of denufosol support its use for early intervention in CF lung disease [abstract]. J Cyst Fibros 2010;9:S21.
29. Accurso FJ, Tian W, Schaberg A, Navratil T, Howenstine MS, Liou TG. Potential of denufosol as an early intervention in CF lung disease: efficacy in patients with minimal pharmacotherapy in a US phase 3 clinical trial. J Cyst Fibros 2010;9:S21.
30. Cystic Fibrosis Foundation. Patient Registry 2004 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2005.
31. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
32. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
33. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365. (Pubitemid 32889511)
34. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997;41:161-165. (Pubitemid 27066337)
35. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
36. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-187. (Pubitemid 29036522)
37. Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ. Reference ranges for spirometry across all ages. Am J Respir Crit Care Med 2008;177:253-260. (Pubitemid 351198367)
38. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III, et al.; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
39. Saiman L, Anstead A, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-1715.
40. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, et al.; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-139.
41. 1 decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-413.
42. 1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-134.
43. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-632.
44. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CM. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol (In press)